MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum

Moderna Inc. (MRNA) shares fell about 6% in premarket trading Wednesday after Citi downgraded the biotech stock from Neutral to Sell, saying its valuation has run ahead of expected revenue and earnings after a sharp 2026 rally.According to the Fly, Citi analyst Geoff Meacham raised his price target…